British Journal of Cancer最新文献_第4页

Fumarate activates the IL-6/JAK/STAT3 pathway by inhibiting KDM4C-mediated H3K36me3 demethylation in FH-knockdown renal cancer cells. 富马酸通过抑制fh敲低肾癌细胞中kdm4c介导的H3K36me3去甲基化，激活IL-6/JAK/STAT3通路。

IF 6.8 1区医学

British Journal of Cancer Pub Date : 2025-09-20 DOI: 10.1038/s41416-025-03195-y

Jie Xian, Xiuyi Pan, Yifan Kang, Linmao Zheng, Xiaoxue Yin, Mengxin Zhang, Yuyan Wei, Junya Tan, Mengni Zhang, Ling Nie, Xueqin Chen, Hao Zeng, Qiao Zhou, Ni Chen

{"title":"Fumarate activates the IL-6/JAK/STAT3 pathway by inhibiting KDM4C-mediated H3K36me3 demethylation in FH-knockdown renal cancer cells.","authors":"Jie Xian, Xiuyi Pan, Yifan Kang, Linmao Zheng, Xiaoxue Yin, Mengxin Zhang, Yuyan Wei, Junya Tan, Mengni Zhang, Ling Nie, Xueqin Chen, Hao Zeng, Qiao Zhou, Ni Chen","doi":"10.1038/s41416-025-03195-y","DOIUrl":"https://doi.org/10.1038/s41416-025-03195-y","url":null,"abstract":"Background: Fumarate is a small molecule metabolite accumulating in fumarate hydratase-deficient renal cell carcinoma (FH-RCC) cells and plays a key role in the malignant transformation. However, the underlying mechanism remains to be investiagted.Methods: The comprehensive transcriptomic profiling of FH-knockdown cells was meticulously examined through RNA-sequencing. Differentially expressed genes were validated using qPCR, WB, and IHC. ChIP-qPCR experiments were conducted to evaluate the histones involved in the process. In vivo and in vitro studies revealed fumarate exerts an inhibitory effect on KDM4C activity. Cell proliferation and invasion assays were utilized to assess the roles of FH and KDM4C in FH-RCC tumorigenesis.Results: We discovered that accumulated fumarate in FH-knockdown ACHN and HK-2 cells competitively binds to α-ketoglutaric acid (α-KG), effectively inhibiting the activity of the histone demethylase KDM4C and significantly increasing the level of histone 3 lysine 36 trimethylation (H3K36me3). The upregulation of H3K36me3 expression triggered the activation of the IL-6/JAK/STAT3 oncogenic signaling pathway and increased the expression of the chemokine CXCL10. Phosphorylated STAT3 (p-STAT3) further enhanced programmed cell death ligand 1 (PD-L1) expression.Conclusions: Collectively, these findings suggest that combining immune checkpoint blockade (ICB) with a STAT3 inhibitor may hold promise for patients with fumarate hydratase-deficient renal cell carcinoma.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145102532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction Note: MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1. 注：MicroRNA-145通过靶向fasin -1抑制结直肠癌的肿瘤生长和转移。

IF 6.8 1区医学

British Journal of Cancer Pub Date : 2025-09-19 DOI: 10.1038/s41416-025-03209-9

Y Feng, J Zhu, C Ou, Z Deng, M Chen, W Huang, L Li

引用次数: 0

Oestradiol and breast cancer prevention: a 40 year history and contemporary perspective. 雌二醇与乳腺癌预防：40年的历史和当代观点。

IF 6.8 1区医学

British Journal of Cancer Pub Date : 2025-09-19 DOI: 10.1038/s41416-025-03115-0

Jack Cuzick, Mitch Dowsett

{"title":"Oestradiol and breast cancer prevention: a 40 year history and contemporary perspective.","authors":"Jack Cuzick, Mitch Dowsett","doi":"10.1038/s41416-025-03115-0","DOIUrl":"https://doi.org/10.1038/s41416-025-03115-0","url":null,"abstract":"Nearly 40 years ago one of us published a conceptual article arguing the case for studies of breast cancer prevention with tamoxifen. Recent observations on the interaction of plasma oestrogen levels with the preventive effect of the aromatase inhibitor anastrozole make it timely to consider the development of oestrogen-targeted prevention of breast cancer and the evidence upon which that development was made. In this article we review the understanding of the aetiology of breast cancer in the mid-1980s; its subsequent development, including the findings from the adjuvant treatment of early breast cancer with tamoxifen and from the trials that assessed tamoxifen as a preventive agent in women at increased risk. We then focus on results from the comparative trials of aromatase inhibitors (AIs) versus tamoxifen and the extension of the use of AIs in trials for prevention. We describe the relationship between plasma levels of oestradiol and its major protein binder, sex hormone binding globulin, on the development of oestrogen receptor positive breast cancer and how these impact on the preventive effect of the AI, anastrozole, in postmenopausal women. Lastly, we speculate on the potential role of routine measurement of oestradiol in managing risk and achieving prevention of breast cancer.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145090957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methodological considerations in assessing HPV prevalence in Barrett's oesophagus progression. 评估Barrett食管进展中HPV患病率的方法学考虑。

IF 6.8 1区医学

British Journal of Cancer Pub Date : 2025-09-19 DOI: 10.1038/s41416-025-03168-1

Talita H A de Oliveira, Lesley A Anderson, Stephanie G Craig, Helen G Coleman, Tarik Gheit, Sandrine McKay-Chopin, Jacqueline Jamison, Damian T McManus, Christopher R Cardwell, Victoria Bingham, Brian T Johnston, Jacqueline A James, Andrew T Kunzmann

引用次数: 0

Accuracy of glomerular filtration rate estimates among patients with cancer. 癌症患者肾小球滤过率估计的准确性。

IF 6.8 1区医学

British Journal of Cancer Pub Date : 2025-09-19 DOI: 10.1038/s41416-025-03190-3

Jennifer S Lees, Edouard L Fu, Anne-Laure Faucon, Benjamin Mp Elyan, Lesley A Inker, Andrew S Levey, Robert J Jones, Richard H Wilson, Patrick B Mark, Juan-Jesus Carrero

{"title":"Accuracy of glomerular filtration rate estimates among patients with cancer.","authors":"Jennifer S Lees, Edouard L Fu, Anne-Laure Faucon, Benjamin Mp Elyan, Lesley A Inker, Andrew S Levey, Robert J Jones, Richard H Wilson, Patrick B Mark, Juan-Jesus Carrero","doi":"10.1038/s41416-025-03190-3","DOIUrl":"https://doi.org/10.1038/s41416-025-03190-3","url":null,"abstract":"Background: Glomerular filtration rate (GFR) estimation is a key issue in determining cancer treatment eligibility and dosing of treatments with narrow therapeutic index. Yet, little is known about the accuracy of GFR estimation among people with cancer in routine care.Methods: In a cross-sectional study including 1611 adults with cancer referred for 1837 determinations of measured GFR (mGFR), we assessed the accuracy of estimated GFR based on creatinine (eGFRcr), cystatin C (eGFRcys) and their combination (eGFRcr-cys). Accuracy was reported as percentage of patients with estimated values within 30% of mGFR; bias and precision as the median and interquartile range of eGFR-mGFR, respectively. Dosing accuracy was assessed by calculating expected dose of carboplatin for area under the curve of 5 mg/mL/min using the Calvert formula.Results: Median age was 68 (IQI 61 to 74) years, 38.5% were female with mean mGFR 75 (SD 30) mL/min; 17% had metastatic disease. Accuracy, bias and precision were best for eGFRcr-cys. Using eGFRcr would recommend an \"overdose\" of carboplatin in 10-20% of participants: this was 3-4 times less common using eGFRcr-cys.Conclusion: eGFRcr-cys equations provide the most accurate estimates of mGFR in patients with cancer, with potential to improve dosing accuracy substantially compared to eGFRcr.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145090890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction Note: Identification of thymidylate synthase as a potential therapeutic target for lung cancer. 注：胸腺苷酸合成酶作为肺癌潜在治疗靶点的鉴定。

IF 6.8 1区医学

British Journal of Cancer Pub Date : 2025-09-19 DOI: 10.1038/s41416-025-03211-1

K Takezawa, I Okamoto, S Tsukioka, J Uchida, M Kiniwa, M Fukuoka, K Nakagawa

引用次数: 0

Retraction Note: Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. 注：血管生成蛋白和信号蛋白与肾细胞癌对序贯治疗的敏感性相关。

IF 6.8 1区医学

British Journal of Cancer Pub Date : 2025-09-19 DOI: 10.1038/s41416-025-03210-2

R Rosa, V Damiano, L Nappi, L Formisano, F Massari, A Scarpa, G Martignoni, R Bianco, G Tortora

引用次数: 0

Birthweight, height, and body mass index in relation to the expression of stem cell markers among women with benign breast biopsies in the Nurses' Health Study II. 在护士健康研究II中，出生体重、身高和体重指数与良性乳腺活检妇女干细胞标志物表达的关系

IF 6.8 1区医学

British Journal of Cancer Pub Date : 2025-09-18 DOI: 10.1038/s41416-025-03194-z

Hannah Oh, Lusine Yaghjyan, Yujing J Heng, Gabrielle M Baker, Brian R Sardella, Matt B Mahoney, Divya Murthy, Bernard Rosner, Rulla M Tamimi

{"title":"Birthweight, height, and body mass index in relation to the expression of stem cell markers among women with benign breast biopsies in the Nurses' Health Study II.","authors":"Hannah Oh, Lusine Yaghjyan, Yujing J Heng, Gabrielle M Baker, Brian R Sardella, Matt B Mahoney, Divya Murthy, Bernard Rosner, Rulla M Tamimi","doi":"10.1038/s41416-025-03194-z","DOIUrl":"10.1038/s41416-025-03194-z","url":null,"abstract":"Background: The amount and activity of breast stem cell population may play an important role in breast carcinogenesis. However, little is known about whether early-life and adult anthropometric measures, including body mass index (BMI), birthweight, and height, are associated with stem cell marker expressions in non-cancerous breast tissue.Methods: Among 730 women with biopsy-confirmed benign breast disease (BBD) in the Nurses' Health Study II, we quantified immunohistochemical staining of stem cell markers (CD44, CD24, ALDH1A1) in histopathologically normal epithelial and stromal breast tissue. Linear regression was conducted to estimate the associations of anthropometric measures with stem cell marker expression, adjusting for potential confounders.Results: BMI at age 18 (≥23.0 vs. <19.0 kg/m2), BMI at benign breast biopsy (≥30.0 vs. <21.0 kg/m2), and change in BMI since age 18 (>7.0 vs. ≤0 kg/m2) were inversely associated with CD44 expression levels in epithelium and stroma combined (β [95% CI]= -0.30 [-0.55, -0.04]; -0.34 [-0.59, -0.08]; -0.38 [-0.65, -0.10]; respectively). Change in BMI since age 18 (>7.0 vs. ≤0 kg/m2) was also inversely associated with ALDH1A1 expression in epithelium (-0.31 [-0.62, -0.001]) and stroma (-0.63 [-1.18, -0.08]). Birthweight and height were not associated.Conclusion: Adiposity measures may be associated with stem cell marker expression among cancer-free women.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12516083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145084957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of CA125- and age-informed risk-based triage for ovarian cancer detection in primary care. 初级保健中基于CA125和年龄的风险分诊对卵巢癌检测的成本效益

IF 6.8 1区医学

British Journal of Cancer Pub Date : 2025-09-17 DOI: 10.1038/s41416-025-03166-3

Runguo Wu, Kirsten D Arendse, Tooba Hamdani, Fiona M Walter, Emma J Crosbie, Borislava Mihaylova, Garth Funston

{"title":"Cost-effectiveness of CA125- and age-informed risk-based triage for ovarian cancer detection in primary care.","authors":"Runguo Wu, Kirsten D Arendse, Tooba Hamdani, Fiona M Walter, Emma J Crosbie, Borislava Mihaylova, Garth Funston","doi":"10.1038/s41416-025-03166-3","DOIUrl":"https://doi.org/10.1038/s41416-025-03166-3","url":null,"abstract":"Background: In England, current practice is cancer antigen 125 (CA125) testing with pelvic ultrasound scan (USS) if CA125 is ≥35 U/mL for triage of women with suspected ovarian cancer (OC) in primary care. However, OC risk varies with CA125 level and age. The Ovatools model predicts OC risk based on age and CA125 levels to support primary care triage.Methods: We evaluated five alternative triage pathways for suspected OC in primary care, using a decision model. Two CA125-USS sequential pathways used Ovatools risk: 1-3% (subsequent USS) and ≥3% (urgent referral), or age-adjusted CA125 thresholds equivalent to Ovatools risks. Three pathways involved concurrent CA125-USS testing, with referral if abnormal USS or one of the following: (1) Ovatools risk ≥3%, (2) CA125 above the equivalent age-adjusted threshold, or (3) CA125 ≥ 35 U/mL. Clinical and cost-effectiveness was compared against current practice for women over and under 50 years.Results: All alternative pathways increased benefits at age ≥50 years, at additional cost. The incremental cost-effectiveness ratios for CA125-USS sequential pathways were below £30,000, dropping below £20,000 if the Ovatools threshold for USS increased to 1.2-1.4% risk.Discussion: For women ≥50 years, the Ovatools and equivalent age-adjusted threshold sequential pathways are cost-effective compared to current practice.","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145079450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methodological reasons for the low prevalence of human papillomavirus infection in progressors versus non-progressors from Barrett's oesophagus to oesophageal adenocarcinoma. 巴雷特食管到食管腺癌的进展者与非进展者相比，人乳头瘤病毒感染流行率低的方法学原因。

IF 6.8 1区医学

British Journal of Cancer Pub Date : 2025-09-17 DOI: 10.1038/s41416-025-03187-y

Shanmugarajah Rajendra, Mohammad Rabiei

引用次数: 0